- Yaky Yanay appointed Co-Chief Executive Officer to serve together with Co-Chief Executive Officer Zami Aberman
- Erez Egozi appointed as Chief Financial Officer
Cynata Therapeutics Lands Japanese Giant Fujifilm
It is not every day that an Aussie minnow lands a deal with a Japanese whale. When Fujifilm took a 9% equity stake in Cynata Therapeutics Ltd (ASX: CYP), it was a major lift for the regenerative medicine company, positioning Cynata to benefit not only from Fujifilm’s resources but also more broadly from current economic strategy within Japan.
Prime Minister of Japan, Shinzō Abe, has committed to building leadership around a new generation of regenerative medicine products involving human cells and tissues and Cynata is now perfectly positioned to take advantage of this in the world’s second largest market for healthcare products. [Read more…]
GMP Grade Cell Cryopreservation Media
AMSBIO has announced the launch of GMP grade STEM-CELLBANKER® manufactured in strict compliance with Japanese, EU, US, and PICS good manufacturing practice guidelines. [Read more…]
Gamida Cell Receives Additional EMA Orphan Drug Designation for NiCord® in HSCT
Phase 3 study of NiCord commenced last month in blood cancer patients
Jerusalem, Israel, March
23, 2017 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that orphan drug designation has been granted by the European Medicines Agency’s (EMA’s) Committee for Orphan Medicinal Products (COMP) regarding NiCord® as a treatment for haematopoietic stem cell transplantation, also commonly known as bone marrow transplantation (BMT).
“We are very encouraged that the EMA has widened NiCord’s orphan drug designation to include BMT, and believe it is an important recognition of the unmet needs in these indications,” said Gamida Cell president and CEO Dr. Yael Margolin. “This broadened regulatory designation adds a key layer of market exclusivity for NiCord as we move forward with our Phase 3 study and prepare for commercialization.” [Read more…]
Scalable Protocol to Differentiate Skeletal Muscle Cells from Stem Cells
AMSBIO announces the availability of the world’s first kit to differentiate human pluripotent stem cells into functional myotubes. The new kit utilizes a highly efficient media based protocol to produce skeletal muscle cells from stem cells in a simple, scalable manner. [Read more…]
- « Previous Page
- 1
- …
- 267
- 268
- 269
- 270
- 271
- …
- 336
- Next Page »